Evidence map›Paper›PMID 36560672›Full record

ArticleViruses2022

Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).

Carla S Coffin, Sarah Haylock-Jacobs, Karen Doucette, Alnoor Ramji, Hin Hin Ko, David K Wong, Magdy Elkhashab, Robert Bailey, Julia Uhanova, Gerald Minuk and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Functional Cure for Hepatitis B Virus: Challenges and Achievements.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 16 institutions in 3 countries.

Carla S CoffinCumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.ORCID 0000-0002-1472-0901
Sarah Haylock-JacobsCumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Karen DoucetteDepartment of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada.ORCID 0000-0002-1660-9166
Alnoor RamjiDepartment of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Hin Hin KoDepartment of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.ORCID 0000-0002-6433-5956
David K WongDepartment of Medicine, University of Toronto, Toronto, ON M5G 2CV, Canada.
Magdy ElkhashabToronto Liver Centre, Toronto, ON M6H 3M1, Canada.
Robert BaileyBailey Health Clinic, Edmonton, AB T5H 4B9, Canada.
Julia UhanovaDepartment of Internal Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
Gerald MinukDepartment of Internal Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
Keith TsoiDepartment of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada.
Alexander WongDepartment of Medicine, University of Saskatchewan, Regina, SK S7N 5A2, Canada.
Mang M MaDepartment of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Edward TamPacific Gastroenterology Associates, Vancouver, BC V6Z 2K5, Canada.
Mayur BrahmaniaMulti Organ Transplant Unit, Department of Medicine, Division of Gastroenterology, Western University, London, ON N6A 3K7, Canada.
Carmine NudoCité-de-la-Santé de Laval, Laval, QC H7M 3L9, Canada.
Julie ZhuFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0000-0001-6057-8275
Christopher F LoweDivision of Medical Microbiology, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada.
Carla OsiowyNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.ORCID 0000-0002-5429-7220
B Cord LethebeCumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Stephen E ConglyCumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.ORCID 0000-0002-3342-3531
Eric K H ChanJanssen Global Services LC, Raritan, NJ 08869, USA.
Angelina Villasis-KeeverJanssen Global Services LC, Raritan, NJ 08869, USA.ORCID 0000-0002-8421-2195
Urbano SbarigiaJanssen Pharmaceuticals NV, 2340 Beerse, Belgium.ORCID 0000-0003-3303-2554
Curtis L CooperDepartment of Medicine, Division of infectious Diseases, University of Ottawa, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0002-3368-3499
Scott FungDepartment of Medicine, University of Toronto, Toronto, ON M5G 2CV, Canada.
University of Calgary · CAJanssen (United States) · USUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Manitoba · CAUniversity of Toronto · CAAlberta Health · CADalhousie University · CAJanssen (Belgium) · BEMcMaster University · CAProvidence Health Care · CAPublic Health Agency of Canada · CAToronto Liver Centre · CAUniversity of Ottawa · CAUniversity of Saskatchewan · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes for individuals with chronic hepatitis B (CHB); however, the effects of varying HBsAg levels on clinical outcomes in diverse cohorts are understudied.

methodsIn this cross-sectional, multicentre, retrospective study, the data on adult subjects enrolled in the Canadian HBV Network with CHB seen from 1 January 2012 to 30 January 2021 with the treatment and virologic data within 1 year of HBsAg testing were analyzed. Patients were tested for HBsAg using qualitative (for HBsAg-negative samples) and/or commercial quantitative assays. Fibrosis or hepatic necroinflammation was determined by the liver stiffness measurement (LSM). The baseline data were summarized using descriptive statistics and compared by using univariable/multivariable analyses.

resultsThis study included 844 CHB patients, with a median age of 49.6 years (IQR 40.1-60.5), and 37% were female. In total, 751 patients (78.6%) had known ethnicity data, and 76.7% self-reported as Asian, 11.4% as Black, 6.8% as White, and 4.8% as other. Among the 844 patients, 237 (28.0%) were HBsAg (-) (<LLOQ), 190 (22.5%) had qHBsAg 1-100, 91 (10.8%) had qHBsAg 100-500, 54 (6.4%) had qHBsAg 500-1000, and 272 (32.2%) had qHBsAg >1000 IU/mL. Overall, 80% (682) had known HBeAg status at the last follow-up, and the majority (87.0%) were HBeAg-negative. In addition, 54% (461/844) had prior antiviral therapy, 19.7% of which (16.3, 23.7,

conclusionIn this retrospective, ethnically diverse cohort study, CHB patients who received antiviral therapy and/or had HBsAg loss were less likely to develop cirrhosis and HCC, confirming the results of the studies in less diverse cohorts. No association was found between the qHBsAg level and fibrosis determined with LSM. Individuals who achieved HBsAg loss had low-level qHBsAg within 1 year of seroclearance.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsAdultAntigens, SurfaceAntiviral AgentsCanadaCohort StudiesCross-Sectional StudiesDNA, ViralFemaleHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansLiver CirrhosisAntigens, SurfaceAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensCanadafunctional cureHBsAg lossmultiethnicquantitative HBsAg

Identifiers

PMID36560672
PMCPMC9781785
OpenAlexW4311001945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.